What does Clinical Trials Claeys do?

Clinical Trials Claeys is a research organisation in Oud-Heverlee. Private Limited, started on 9 March 2004, 2 establishments.

What is the address of Clinical Trials Claeys?

The registered office of Clinical Trials Claeys is located at Kloosterweg 20, 3052 Oud-Heverlee.

Is Clinical Trials Claeys still active?

Yes. According to the CBE (30 September 2026) Clinical Trials Claeys is active, legal situation “Normale toestand”, started on 9 March 2004.

Is Clinical Trials Claeys registered on Peppol?

Yes, Clinical Trials Claeys is registered on the Peppol network with ID 0208:0863913573.

What is the enterprise number of Clinical Trials Claeys?

The enterprise number of Clinical Trials Claeys is BE0863913573.

When was Clinical Trials Claeys founded?

Clinical Trials Claeys was founded on 9 March 2004.

Who are the directors of Clinical Trials Claeys?

According to the 2025 annual accounts, the directors of Clinical Trials Claeys are: Wim Claeys.

Is Clinical Trials Claeys a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 March 2004; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 2 establishments in the CBE.

How much profit did Clinical Trials Claeys make in 2025?

Clinical Trials Claeys posted a profit after taxes of € 175,643 in financial year 2025.

What is the revenue of Clinical Trials Claeys?

As a small company, Clinical Trials Claeys is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 247,436.

Clinical Trials Claeys (Private Limited) - Oud-Heverlee

Dossier Clinical Trials Claeys, printed on 30 September 2026 from databakkes.be/en/0863913573/clinical-trials-claeys. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Clinical Trials Claeys from Oud-Heverlee, company number BE0863913573, closed financial year 2025 with a result of € 175,643 after tax. For that financial year Clinical Trials Claeys recorded a gross margin of € 247,436 and equity of € 757,494. Compared with financial year 2024, the result moved from € 176,160 to € 175,643. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 25, 2026.

What it is worth Growing

€ 757,494

▲ 13% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 175,643

Profit after tax over the fiscal year.

Cash in the bank

€ 237,675

▲ 154% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 91,107 paid out

52 % of the profit went to the shareholders, the rest stayed in the company.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 588

▼ 48% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 22,747

▼ 36% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 202,408 Gross margin 2022: € 202,408 First fiscal year in the series	€ 177,532 Gross margin 2023: € 177,532 ▼ 12% vs 2022 (€ 202,408) Unfavourable step	€ 247,795 Gross margin 2024: € 247,795 ▲ 40% vs 2023 (€ 177,532) Favourable step	€ 247,436 Gross margin 2025: € 247,436 Unchanged (€ 247,795) Unfavourable step
Profit after taxes	€ 140,917 Profit after taxes 2022: € 140,917 First fiscal year in the series	€ 124,264 Profit after taxes 2023: € 124,264 ▼ 12% vs 2022 (€ 140,917) Unfavourable step	€ 176,160 Profit after taxes 2024: € 176,160 ▲ 42% vs 2023 (€ 124,264) Favourable step	€ 175,643 Profit after taxes 2025: € 175,643 Unchanged (€ 176,160) Unfavourable step
Equity	€ 486,260 Equity 2022: € 486,260 First fiscal year in the series	€ 565,862 Equity 2023: € 565,862 ▲ 16% vs 2022 (€ 486,260) Favourable step	€ 672,959 Equity 2024: € 672,959 ▲ 19% vs 2023 (€ 565,862) Favourable step	€ 757,494 Equity 2025: € 757,494 ▲ 13% vs 2024 (€ 672,959) Favourable step	▲ 13%
Total debts	€ 27,159 Total debts 2022: € 27,159 First fiscal year in the series	€ 58,532 Total debts 2023: € 58,532 ▲ 116% vs 2022 (€ 27,159) Unfavourable step	€ 107,271 Total debts 2024: € 107,271 ▲ 83% vs 2023 (€ 58,532) Unfavourable step	€ 114,978 Total debts 2025: € 114,978 ▲ 7% vs 2024 (€ 107,271) Unfavourable step	▲ 7%
Cash	€ 377,594 Cash 2022: € 377,594 First fiscal year in the series	€ 388,918 Cash 2023: € 388,918 ▲ 3% vs 2022 (€ 377,594) Favourable step	€ 93,707 Cash 2024: € 93,707 ▼ 76% vs 2023 (€ 388,918) Unfavourable step	€ 237,675 Cash 2025: € 237,675 ▲ 154% vs 2024 (€ 93,707) Favourable step	▲ 154%
Land & buildings	€ 3,974 Land & buildings 2022: € 3,974 First fiscal year in the series	€ 2,779 Land & buildings 2023: € 2,779 ▼ 30% vs 2022 (€ 3,974) Unchanged	€ 1,584 Land & buildings 2024: € 1,584 ▼ 43% vs 2023 (€ 2,779) Unchanged	€ 7,542 Land & buildings 2025: € 7,542 ▲ € 5,958 vs 2024 (€ 1,584) Unchanged	▲ € 5,958
Retained profit	€ 467,660 Retained profit 2022: € 467,660 First fiscal year in the series	€ 547,262 Retained profit 2023: € 547,262 ▲ 17% vs 2022 (€ 467,660) Favourable step	€ 654,359 Retained profit 2024: € 654,359 ▲ 20% vs 2023 (€ 547,262) Favourable step	€ 738,894 Retained profit 2025: € 738,894 ▲ 13% vs 2024 (€ 654,359) Favourable step	▲ 13%
Dividend	€ 19,782 Dividend 2022: € 19,782 First fiscal year in the series	€ 44,662 Dividend 2023: € 44,662 ▲ 126% vs 2022 (€ 19,782) Unchanged	€ 69,064 Dividend 2024: € 69,064 ▲ 55% vs 2023 (€ 44,662) Unchanged	€ 91,107 Dividend 2025: € 91,107 ▲ 32% vs 2024 (€ 69,064) Unchanged	▲ 32%
Balance sheet total	€ 513,419 Balance sheet total 2022: € 513,419 First fiscal year in the series	€ 624,394 Balance sheet total 2023: € 624,394 ▲ 22% vs 2022 (€ 513,419) Unchanged	€ 780,230 Balance sheet total 2024: € 780,230 ▲ 25% vs 2023 (€ 624,394) Unchanged	€ 872,473 Balance sheet total 2025: € 872,473 ▲ 12% vs 2024 (€ 780,230) Unchanged	▲ 12%

Key figures of Clinical Trials Claeys, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Clinical Trials Claeys?

What happened at Clinical Trials Claeys in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 25, 2026 New annual accounts for financial year 2025: profit of € 175,643. filed late Source: NBB ↗
Jul 5, 2020 New establishment in Leuven. KBO
2013 Wim Claeys became a director. NBB
Mar 9, 2004 New establishment in Leuven. KBO
Mar 9, 2004 Start of the company according to the CBE. KBO

In short

From € 140,917 profit in 2022 to € 175,643 profit in 2025.

Paid € 277,467 in corporate taxes since 2022.

Best year ever: 2024, with € 176,160 profit.

Paid out € 224,615 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Clinical Trials Claeys? We notify you, reason included.

Follow Clinical Trials Claeys

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Wim Claeys

Clinical Trials Claeys

Behind Clinical Trials Claeys is Wim Claeys.

See the full network in the app

Directors

According to the 2025 annual accounts

Wim Claeys

Director

since 2013

Establishments

Establishment units

Physical locations of this company

Registered office

Kloosterweg 20

3052 Oud-Heverlee

2.135.906.346

Tweekleinewegenstraat 105

3001 Leuven

Active since 9 March 2004

2.305.618.833

Ziekelingenstraat 35

3000 Leuven

Active since 5 July 2020

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0863.913.573

VAT number

BE 0863.913.573

Registered office

Kloosterweg 20, 3052 Oud-Heverlee

Names & denominations

Clinical Trials Claeys · C.T.C.

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

9 March 2004

Peppol

Active · Active since 1 Jun 2026

Activities · NACE

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied